JumpStart Ventures Invests $250,000 in Thermalin Diabetes Inc.
03/29/2010
"Over the next 20 years, worldwide insulin sales are expected to grow from $12 billion to $54 billion, JumpStart Ventures partner Ted Frank told Crain's Cleveland Business. "That growth, combined with the medical community's interest in insulin with higher performance, fewer side effects, and storage flexibility, position Thermalin's pipeline to be in high demand."
Thermalin will use the funds to validate its insulin analogs' characteristics, locate a manufacturer, and proceed in the investigational drug process with the FDA.
The company's products include a faster meal-time insulin that is expected to reduce long-term side effects. The insulin can also be stored at higher temperatures, which would make transport and delivery easier.
Most Read
-
-
A Site Selector’s Checklist for Locating in the U.S.
Location USA 2019
-
Where to Invest in the Booming Aerospace Manufacturing Industry
2019 Auto/Aero Site Guide
-
What Should High-Growth Companies Look for in a Community?
Q4 2019
-
The Trade War and Its Impact on the Location Decision Process
Q4 2019
-
A Changing Food Manufacturing Industry
2017 Food Processing
-
33rd Annual Corporate Survey & the 15th Annual Consultants Survey
Q1 2019